GE HealthCare’s SOFIE deal deepens a complicated relationship with Lantheus
GE HealthCare’s planned $945m acquisition of SOFIE Biosciences has been read as a move to protect supply for Flyrcado, its cardiac PET agent
The post GE HealthCare’s SOFIE deal deepens a complicated relationship with Lantheus appeared first on Medical Device Network .